China Securities Intelligent Finance ST Weiming(002581) announced on November 7 that its wholly-owned subsidiary, Shandong Yandu Biotechnology Co., Ltd., has independently developed a Class I innovative drug.The Phase III pivotal registration clinical trial of recombinant human nerve growth factor SMR001 eye drops for the treatment of moderate to severe dry eye disease recently received approval from the Ethics Committee of Beijing Tongren Hospital, affiliated with Capital Medical University, the lead institution, marking the official commencement of the project.
　　The announcement stated that SMR001 eye drops are a key innovative ophthalmic biological drug developed by the company. Utilizing a Chinese hamster ovary cell (CHO) expression system, it is the first domestically produced eye drop formulation with recombinant human nerve growth factor as its active ingredient. This product, by repairing damaged corneal nerves and promoting epithelial regeneration, is expected to become a novel treatment option for moderate to severe dry eye syndrome.
　　In accordance with the requirements of the National Medical Products Administration, the company will collaborate with authoritative domestic clinical research institutions to advance subsequent key clinical studies, verify the safety and efficacy of the product, and provide core data support for subsequent market registration. The company also cautions that drug development is characterized by high investment, high risk, and a long cycle; the progress and results of clinical trials are subject to various factors and therefore involve uncertainty.
　　ST Weiming's business segments include biopharmaceutical products such as mouse nerve growth factor, interferon, and vaccines. In the first three quarters, the company achieved total operating revenue of 212 million yuan, a year-on-year decrease of 32.62%; net profit attributable to the parent company was a loss of 68.8107 million yuan, compared to a profit of 14.6263 million yuan in the same period last year.

https://finance.eastmoney.com/a/202511073557981760.html